Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407314 · ClinicalTrials.gov registry record · Phase 4
Ticagrelor and Peripheral Arterial Disease
A Phase 4 study, sponsored by Arkansas Heart Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT02407314: Clinical Trial Phase 4 study, sponsored by Arkansas Heart Hospital.
NCT02407314 is a Phase 4 study that was terminated before completion, run by Arkansas Heart Hospital. The registered enrollment target is 26 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02407314, a Phase 4 study, was terminated before completion, sponsored by Arkansas Heart Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is an interventional study assessing the effectiveness of Ticagrelor on the reduction of thrombus burden using optical coherence tomography in patients undergoing peripheral artery stenting.
Primary Outcome
Intraluminal clot volume will be assessed by Optical Coherence Tomography using a Core Lab.
Interventions
- DRUG Aspirin
- DEVICE Optical Coherence Tomography
- PROCEDURE Percutaneous Peripheral Intervention
- OTHER Ankle Brachial Index
- OTHER Six minute walk distance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-01-17 |
| Phase | Phase 4 |
Why NCT02407314 stopped before completion
NCT02407314 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Aspirin is the first listed.
NCT02407314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02407314 about?
NCT02407314 is a clinical study titled "Ticagrelor and Peripheral Arterial Disease". This is an interventional study assessing the effectiveness of Ticagrelor on the reduction of thrombus burden using optical coherence tomography in patients undergoing peripheral artery stenting.
What is the current status of trial NCT02407314?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2015-06. Estimated completion is 2017-01-17.
What interventions are being tested in trial NCT02407314?
The interventions under investigation include: Aspirin (DRUG), Optical Coherence Tomography (DEVICE), Percutaneous Peripheral Intervention (PROCEDURE), Ankle Brachial Index (OTHER), Six minute walk distance (OTHER).
Who is sponsoring clinical trial NCT02407314?
This trial is sponsored by Arkansas Heart Hospital, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02407314's enrollment target sits among peer trials
26 1655th of 2000 higher than 332 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia